The results from this study indicate that Rolontis, a novel long‐acting G‐CSF, conferred comparable efficacy benefits to pegfilgrastim on duration of severe neutropenia and presented no new safety concerns when administered to patients with breast cancer receiving docetaxel and cyclophosphamide as adjuvant or neoadjuvant chemotherapy. Here, CSF3 is linked to neutropenia.